🎉 M&A multiples are live!
Check it out!

Square Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Square Pharma and other public comps.

See Square Pharma Valuation Multiples

Square Pharma Overview

About Square Pharma

Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceuticals products, Basic chemical products, and animal health products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs like paracetamol, clotrimazole, antiallergic, Nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs. Company also provides devices such as AnsuPen and AnsuPen Twist. The company operates in Bangladesh and sells its products locally and internationally.


Founded

1964

HQ

Bangladesh
Employees

12.5K+

Financials

LTM Revenue $618M

LTM EBITDA $190M

EV

$1.2B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Square Pharma Financials

Square Pharma has a last 12-month revenue of $618M and a last 12-month EBITDA of $190M.

In the most recent fiscal year, Square Pharma achieved revenue of $585M and an EBITDA of $211M.

Square Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Square Pharma valuation multiples based on analyst estimates

Square Pharma P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $481M $524M $585M $618M XXX
Gross Profit $247M $258M $276M XXX XXX
Gross Margin 51% 49% 47% XXX XXX
EBITDA $189M $196M $211M $190M XXX
EBITDA Margin 39% 37% 36% 31% XXX
Net Profit $152M $158M $175M XXX XXX
Net Margin 32% 30% 30% XXX XXX
Net Debt n/a n/a n/a XXX XXX

Financial data powered by Morningstar, Inc.

Square Pharma Stock Performance

As of February 10, 2025, Square Pharma's stock price is BDT 216 (or $2).

Square Pharma has current market cap of BDT 192B (or $1.6B), and EV of BDT 146B (or $1.2B).

See Square Pharma trading valuation data

Square Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.2B $1.6B XXX XXX XXX XXX $0.21

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Square Pharma Valuation Multiples

As of February 10, 2025, Square Pharma has market cap of $1.6B and EV of $1.2B.

Square Pharma's trades at 2.0x LTM EV/Revenue multiple, and 6.4x LTM EBITDA.

Analysts estimate Square Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Square Pharma and 10K+ public comps

Square Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.2B XXX XXX XXX
EV/Revenue 2.0x XXX XXX XXX
EV/EBITDA 6.0x XXX XXX XXX
P/E 8.7x XXX XXX XXX
P/E/Growth 0.8x XXX XXX XXX
EV/FCF 10.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Square Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Square Pharma Valuation Multiples

Square Pharma's NTM/LTM revenue growth is 9%

Square Pharma's revenue per employee for the last fiscal year averaged $47K, while opex per employee averaged $10K for the same period.

Over next 12 months, Square Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Square Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Square Pharma and other 10K+ public comps

Square Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 12% XXX XXX XXX XXX
EBITDA Margin 33% XXX XXX XXX XXX
EBITDA Growth 7% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 42% XXX XXX XXX XXX
Revenue per Employee $47K XXX XXX XXX XXX
Opex per Employee $10K XXX XXX XXX XXX
S&M Expenses to Revenue 6% XXX XXX XXX XXX
G&A Expenses to Revenue 1% XXX XXX XXX XXX
R&D Expenses to Revenue 0% XXX XXX XXX XXX
Opex to Revenue 21% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Square Pharma Public Comps

See valuation multiples for Square Pharma public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Square Pharma M&A and Investment Activity

Square Pharma acquired  XXX companies to date.

Last acquisition by Square Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Square Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Square Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Square Pharma

When was Square Pharma founded? Square Pharma was founded in 1964.
Where is Square Pharma headquartered? Square Pharma is headquartered in Bangladesh.
How many employees does Square Pharma have? As of today, Square Pharma has 12.5K+ employees.
Is Square Pharma publicy listed? Yes, Square Pharma is a public company listed on DHA.
What is the stock symbol of Square Pharma? Square Pharma trades under SQURPHARMA ticker.
Who are competitors of Square Pharma? Similar companies to Square Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Square Pharma? Square Pharma's current market cap is $1.6B
What is the current revenue of Square Pharma? Square Pharma's last 12-month revenue is $618M.
What is the current EBITDA of Square Pharma? Square Pharma's last 12-month EBITDA is $190M.
What is the current EV/Revenue multiple of Square Pharma? Current revenue multiple of Square Pharma is 2.0x.
What is the current EV/EBITDA multiple of Square Pharma? Current EBITDA multiple of Square Pharma is 6.4x.
What is the current revenue growth of Square Pharma? Square Pharma revenue growth between 2023 and 2024 was 12%.
Is Square Pharma profitable? Yes, Square Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.